Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Finished Goods (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed Finished Goods for 15 consecutive years, with $14.7 million as the latest value for Q1 2026.

  • For Q1 2026, Finished Goods rose 72.88% year-over-year to $14.7 million; the TTM value through Mar 2026 reached $14.7 million, up 72.88%, while the annual FY2025 figure was $9.4 million, 14.7% up from the prior year.
  • Finished Goods hit $14.7 million in Q1 2026 for Corcept Therapeutics, up from $9.4 million in the prior quarter.
  • Across five years, Finished Goods topped out at $14.7 million in Q1 2026 and bottomed at $5.5 million in Q1 2022.
  • Average Finished Goods over 5 years is $8.2 million, with a median of $8.1 million recorded in 2023.
  • Year-over-year, Finished Goods decreased 19.47% in 2025 and then surged 72.88% in 2026.
  • Corcept Therapeutics' Finished Goods stood at $9.2 million in 2022, then fell by 15.9% to $7.7 million in 2023, then rose by 6.01% to $8.2 million in 2024, then increased by 14.7% to $9.4 million in 2025, then soared by 56.11% to $14.7 million in 2026.
  • According to Business Quant data, Finished Goods over the past three periods came in at $14.7 million, $9.4 million, and $8.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.